Diabetes, high BMI, and history of metformin common in adolescents with GLP-1RA

WEDNESDAY, Oct. 16, 2024 (HealthDay News) — Patients aged 10 to 17 years prescribed glucagon-like peptide 1 receptor (GLP-1RA) agonists are more likely to have comorbid type 2 diabetes and a high body mass index. , and a prior prescription for metformin, according to a research letter published online Oct. 16 in Open JAMA Network.

Margaret G. Miller, of Case Western Reserve University in Cleveland, and colleagues characterized patient demographics and prevalence of comorbidities among 11,380 matched patients (aged 10 to 17 years) who did or did not receive initial prescription for a PR GLP-1. during visits from 2019 to 2023.

Researchers found that patients prescribed GLP-1 ARs were more often women (60.4 percent; P International Statistical Classification of Diseases and Related Health Problems, Tenth Revision meet diabetes diagnostic codes type 2 (46.2 percent), metabolic syndrome (16.0 percent), and type 1 diabetes (18.6 percent) were more common than in controls with body mass index ≥. 95th percentile was more common among patients receiving a GLP-1 RA than among those not receiving one (87.1 versus 32.9 percent of patients with a GLP-1 RA prescription had a prior prescription). insulin, metformin or orlistat.

“A thorough understanding of the long-term impacts (physical, mental, sociocultural, etc.) of GLP-1 RAs on preadolescent and adolescent patients is crucial to better inform prescribing practices and constitutes an important direction for future studies” authors write.

Summary/Full text